10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# Anti-IL-18BP Reference Antibody (Novartis patent anti-IL-18)

Catalog # APR11464

## Product Information

| | |
|---|---|
| **Application** | Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA |
| **Primary Accession** | Q14116 |
| **Reactivity** | Human |
| **Clonality** | Monoclonal |
| **Isotype** | IgG1 |
| **Calculated MW** | 22326 |

## Additional Information


| | |
|---|---|
| **Target/Specificity** | IL-18 |
| **Expression system** | CHO |

## Protein Information


| | |
|---|---|
| **Name** | IL18 ( HGNC:5986) |
| **Synonyms** | IGIF, IL1F4 |
| **Function** | Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed:10653850). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed:14528293, PubMed:25500532, PubMed:37993714). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed:10653850). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744). |
| **Cellular Location** | Cytoplasm, cytosol. Secreted. Note=The precursor is cytosolic (PubMed:33883744). In response to inflammasome-activating signals, cleaved and secreted (PubMed:33883744, PubMed:37993712, PubMed:37993714). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744, PubMed:37993714). In contrast, the precursor form is not released, due to the presence of an acidic region that is proteolytically removed by CASP1, CASP4 or CASP5 during maturation (PubMed:33883744, PubMed:37993714). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059). |

| | |
|---|---|
| **Tissue Location** | [Isoform 2]: Expressed in ovarian carcinoma but undetectable in normal ovarian epithelial cells. Resistant to proteolytic activation by caspase-1 and -4 |


## Images




Anti-IL-18 Reference Antibody (Novartis patent anti-IL-18) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-IL-18BP Reference Antibody (Novartis patent anti-IL-18) is 100%, determined by SEC-HPLC.




Immobilized N-His-SUMO-Hu-IL-18, It's target at 2 μg/mL can bind Anti-IL-18BP Reference Antibody (Novartis patent anti-IL-18), EC50= 0.08693 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.